Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31221861 | 1.00 | KDM4C (0.43) | KDM4CICAM1SELEL3MBTL1ALDH1A1 | |
| SCHEMBL30486583 | 0.88 | ALDH1A1 (0.41) | KDM4CICAM1SELEL3MBTL1ALDH1A1 | |
| SCHEMBL25281689 | 0.88 | ALDH1A1 (0.41) | KDM4CICAM1SELEL3MBTL1ALDH1A1 | |
| SCHEMBL25395382 | 0.83 | KDM4C (0.40) | KDM4CICAM1SELEL3MBTL1NPC1 | |
| SCHEMBL31221960 | 0.83 | KDM4C (0.40) | KDM4CICAM1SELEL3MBTL1NPC1 | |
| SCHEMBL25396966 | 0.81 | ICAM1 (0.41) | KDM4CICAM1SELEL3MBTL1NPC1 | |
| SCHEMBL31221880 | 0.81 | ICAM1 (0.41) | KDM4CICAM1SELEL3MBTL1NPC1 | |
| SCHEMBL1548491 | 0.81 | KDM4C (0.43) | KDM4CICAM1SELEL3MBTL1ALDH1A1 | |
| SCHEMBL25399049 | 0.80 | KDM4C (0.40) | KDM4CICAM1SELEL3MBTL1NPC1 | |
| SCHEMBL2899380 | 0.77 | KDM4C (0.42) | KDM4CICAM1SELEL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023176957-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | 日本農薬株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| EP-2314585-B1 | Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2314585-A1 | Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity | Japan Tobacco, Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1777225-A1 | FUSED BENZAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | TRPV1, TRPV2, TRPA1 | KDM4C 3052/4885ICAM1 170/4885SELE 3741/4885 |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | KDM4C 4322/4885ICAM1 4301/4885SELE 3808/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | KDM4C 4322/4885ICAM1 4301/4885SELE 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.